Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Graig Suvannavejh initiated a Buy rating on Zentalis Pharmaceuticals (ZNTL) with an $8.00 price target. This contrasts with the broader market consensus, which holds a Moderate Buy rating and an average price target of $6.40 for the healthcare stock.
Zentalis Pharmaceuticals received a Buy rating and an $8.00 price target from Mizuho Securities analyst Graig Suvannavejh today.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Suvannavejh covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Axsome Therapeutics, and Immuneering. According to TipRanks, Suvannavejh has an average return of 21.5% and a 48.98% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zentalis Pharmaceuticals with a $6.40 average price target.